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Opposing Effects of Ras on p53: Transcriptional
Activation of mdm2 and Induction of p19ARF
pRb (Xiao et al., 1995) or through interaction with the
E2F/DP1 complex (Martin et al., 1995). These functions
of Mdm2 are less well characterized than its role in p53
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that p53 regulation is the major function of this protein*University of California, San Francisco
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tion (Kamijo et al., 1998; Pomerantz et al., 1998). An
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Rehovot 76100 p19ARF binds to Mdm2, sequesters Mdm2 in nucleolar
Israel structures, and allows accumulation of p53 (Tao and
‡Kyushu University Levine, 1999; Sherr and Weber, 2000). On the other hand,
Fukuoka, Japan p19ARF directly inhibits Mdm2 ubiquitin ligase activity,
suggesting a more direct role in Mdm2 regulation (Honda
and Yasuda, 1999). p14ARF, the human homolog of p19ARF,
Summary is induced by E2F, myc and Ras, and thus provides a
possible link from mitogenic signaling pathways to p53
induction (Bates et al., 1998; Palmero et al., 1998; ZindyMdm2 acts as a major regulator of the tumor suppres-
et al., 1998). The Ras-regulated Raf/MEK/ERK kinasesor p53 by targeting its destruction. Here, we show
pathway has been reported to activate CDK4/cyclin Dthat the mdm2 gene is also regulated by the Ras-driven
kinases, thereby phosphorylating pRb, which in turnRaf/MEK/MAP kinase pathway, in a p53-independent
leads to release of E2F-1 (Albanese et al., 1995; Peepermanner. Mdm2 induced by activated Raf degrades p53
et al., 1997). The p14ARF promoter contains several E2F-1in the absence of the Mdm2 inhibitor p19ARF. This regu-
binding sites and its activity was shown to be enhancedlatory pathway accounts for the observation that cells
by overexpression of E2F-1 (Bates et al., 1998). Thetransformed by oncogenic Ras are more resistant to
Ras/Raf/MEK/MAP kinase pathway can therefore leadp53-dependent apoptosis following exposure to DNA
indirectly to accumulation of p14ARF and inhibition ofdamage. Activation of the Ras-induced Raf/MEK/MAP
Mdm2 activity.
kinase may therefore play a key role in suppressing Mdm2 expression is often increased following mito-
p53 during tumor development and treatment. In pri- genic activation. Treatment of cells in culture with basic
mary cells, Raf also activates the Mdm2 inhibitor FGF increases levels of Mdm2 protein and cells constitu-
p19ARF. Levels of p53 are therefore determined by op- tively exposed to a basic FGF autocrine loop are more
posing effects of Raf-induced p19ARF and Mdm2. refractory to killing by cisplatin, which to a large extent
occurs through p53-mediated apoptosis (Shaulian et
Introduction al., 1997). More recently, a screen for transcripts that
accumulate in cells harboring a chimeric M-CSF/PDGF
Mdm2 was originally identified as an amplified gene in receptor identified mdm2 as an immediate early gene
a spontaneously transformed derivative of BALB/c cell (Fambrough et al., 1999). In addition, we have observed
line 3T3 DM, which caused tumors when injected into high levels of Mdm2 protein expression in human tumor
nude mice (Fakharzadeh et al., 1991). A possible mecha- cell lines that have little, if any, functional p53 (Ries
nism for the transforming properties of mdm2 has been et al., 2000). These data suggest regulation of mdm2
provided by reports demonstrating that Mdm2 is a major expression by p53-independent pathways triggered by
regulator of the tumor suppressor p53. It binds directly growth factors.
to p53 and inhibits its transcriptional activity (Momand A common feature of signaling by diverse growth fac-
et al., 1992; Oliner et al., 1992, 1993). Mdm2 is a tran- tors is the activation of the Ras/Raf/MEK/MAP kinase
scriptional target of p53 (Barak et al., 1993; Wu et al., pathway. We therefore explored the possibility that this
1993; Leng et al., 1995). p53-responsive elements have pathway is responsible for mdm2 induction. We report
been identified in the intronic promoter of the mdm2 that the mdm2 promoter is indeed a target of the Ras/
gene, and interaction of p53 with these sites has been Raf/MEK/MAP kinase pathway. Hence, activation of Ras
well documented (Juven et al., 1993; Barak et al., 1994; during normal cell signaling or through mutation in neo-
Zauberman et al., 1995). Induction of mdm2 transcrip- plastic transformation, can suppress p53 and thus facili-
tion by p53 establishes a negative feedback loop, in tate cell proliferation and survival.
which p53 itself initiates its own destruction (Picksley
and Lane, 1993). Results
Mdm2 may have additional functions that are not di-
rectly related to p53. It affects cell growth in a p53- Mdm2 Expression Is Regulated
independent manner, possibly through interactions with by the Ras/Raf Pathway
Mdm2 protein can be induced by exposure of cells to
basic FGF (Shaulian et al., 1997) or IGF-1 (Leri et al.,§ To whom correspondence should be addressed (e-mail: mccormick@
1999). Likewise, mdm2 mRNA accumulates upon activa-cc.ucsf.edu).
k These authors contributed equally to this work. tion of the PDGF receptor (Fambrough et al., 1999).
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Figure 1. Induction of mdm2 Transcription
by Activated Ras and Raf
(A) Mdm2 transcriptional induction by consti-
tutively active H-Ras(G12V) in NIH-3T3 cells.
NIH-3T3 cells were infected with retroviruses
encoding H-Ras(G12V) or empty vector. After
selection with G418, total cellular RNA was
prepared and subjected to Northern blot
analysis using a 1.5 kb fragment spanning
the coding region of mdm2 as a probe. For
Western blot analysis, cells were directly lysed
with Laemmli buffer, and equal amounts of to-
tal protein were subjected to immunoblotting.
(B) Activation of Raf is sufficient to induce
mdm2 transcription in NIH-3T3 cells. NIH-3T3
cells expressing a 4-Hydroxy-Tamoxifen (4-HT)
inducible DB-Raf:ER* construct were treated
with 10 nM 4-HT, total cellular RNA and pro-
tein harvested at the times indicated and sub-
jected to Northern blot analysis or Western
blot analysis.
(C) Transcriptional induction of mdm2 by Raf
is independent of p53. p532/2 mouse em-
bryonic fibroblasts (MEF) harboring the 4-HT
inducible EGFP-DRaf1:ER construct were
treated with 100 nM 4-HT, and total cellular
RNA and protein was harvested after 24 hr.
(D) Transcription by activated Raf initiates
mainly from the internal mdm2 promoter (P2).
Total cellular RNA was prepared from the cell
lines as indicated (top). Ten micrograms of
each RNA was subjected to RNase protection analysis. Lanes 1 and 7 contain the probe alone and the control reaction consisting of 10 mg
of yeast tRNA, respectively. Composition and sizes (in nucleotides) of potential RNase-resistant fragments are indicated in the schematic
representation.
Since Ras is downstream of all these mitogens, we The murine mdm2 gene has two promoters, an internal
promoter (P2), which responds directly to p53 activation,tested whether the Ras pathway is responsible for
mdm2 induction. NIH-3T3 cells expressing an activated and an upstream constitutive promoter (P1), which is not
affected by p53 (Barak et al., 1994). The cDNA riboprobeRas allele, H-Ras (G12V), were analyzed for mdm2
mRNA and protein expression. Figure 1A shows that used for RNase protection assay spans exon 1, exon 2,
and part of exon 3 (Figure 1D), allowing discriminationexpression of constitutively active Ras resulted in in-
creased levels of mdm2 mRNA and protein. between P1 and P2 transcripts. Transcription from the
P2 promoter was dramatically induced in response toRas targets several distinct downstream effectors, of
which the best characterized are Raf kinase, PI3-kinase, activation of the Raf kinase, whereas a more moderate
induction occurred with transcription from P1 (Figureand RalGDS (Marshall, 1995; Katz and McCormick, 1997;
Rodriguez-Viciana et al., 1997). We examined the effects 1D, lanes 2, 3, and 4). Induction of P2 transcription oc-
curs in a p53-independent manner as p53-deficientof a conditionally active Raf kinase on cellular Mdm2
levels. This conditional Raf kinase consists of the kinase MEFs show similar enhanced transcription arising from
P2 (Figure 1D, lanes 5 and 6). Note that only P1 tran-domain of B-Raf fused to a modified form of the hormone
binding domain of the mouse estrogen receptor, which scripts are detectable in control NIH-3T3 cells.
renders the receptor insensitive to estrogen, but still
sensitive for the estrogen analog 4-hydroxy-tamoxifen
(4-HT) (Samuels et al., 1993; Woods et al., 1997). NIH3T3 Analysis of Ras-Responsive Elements
within the mdm2 P2 Promotercells stably expressing the DB-Raf:ER* were treated with
10 nM 4-HT (Woods et al., 1997). Addition of 4-HT re- To determine the role of Raf activation on basal mdm2
transcription, the effect of a constitutively activated formsulted in remarkable MAPK activation and accumulation
of high levels of mdm2 mRNA and protein (Figure 1B). of Raf (Raf-CAAX) on mdm2 promoter activity was ex-
amined in p53-deficient 10(1) cells (Stokoe et al., 1994).To rule out any contribution of p53 to the increased
Mdm2 levels after Raf activation, we assessed Mdm2 Raf-CAAX expression induced mdm2 P2 promoter ac-
tivity 5- to 6-fold (Figure 2B). Sequence analysis of theexpression in p532/2 mouse embryo fibroblasts (MEFs)
stably expressing EGFP-DRaf1:ER (Woods et al., 1997). mdm2 P2 promoter revealed the existence of binding
sites for transcription factors of the AP-1 and Ets familyFigure 1C shows increased transcription and accumula-
tion of Mdm2 protein in response to Raf/MEK/MAPK (Figure 2A), which have been shown to be responsive
to ERK activation in other genes. To determine the re-activation occurred also in p532/2 fibroblasts. In a time
course experiment using NIH3T3(DB-Raf:ER*) cells, ele- gion of the mdm2 P2 promoter required for regulation
by Raf, several mdm2 P2 59 promoter deletions werevated mdm2 mRNA levels can be detected as early as
4 hr after Raf activation and increase steadily (data not generated and transfected in the presence of Raf-CAAX
into 10(1) cells. Figure 2B shows that the upstream Etsshown). Thus, the Ras/Raf/MEK/MAP kinase pathway
induces increased expression of mdm2 mRNA and site within the P2 promoter (designated EtsA in Figure
2B) of the mdm2 gene is important for the Raf-inducedMdm2 protein in a p53-independent manner.
Opposing Effects of Ras on p53
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Figure 2. Ets/AP-1 Motifs in the Intronic P2
Promoter Mediate Transcription of the mdm2
Gene upon Raf Activation
(A) DNA sequence of the intronic mdm2 pro-
moter (P2). The Ets and AP-1 binding sites
are indicated by arrows, the p53-responsive
elements are boxed, and the TATA box is
marked in bold.
(B) Various 59 deletions of the mdm2 pro-
moter were cloned in front of the firefly lucifer-
ase gene. 10(1) cells were cotransfected with
1 mg of each luciferase reporter construct and
either 100 ng of a vector expressing CAAX-
tagged Raf or the parental control vector
(pcDNA3). Luciferase activity was determined
using a luminometer.
(C) Using in vitro mutagenesis, Ets and AP-1
sites of the mdm2 promoter luciferase con-
struct L1 as in (B) were selectively mutated.
Luciferase activity of the mutated promoter
constructs in 10(1) cells was determined. All
promoter constructs were responsive to co-
transfected p53 (indicated as 1).
(D) 10(1) were transiently transfected with 1
mg of the mdm2 promoter luciferase con-
struct L1 combined with 100 ng of plasmids
directing expression of either constitutively
active MEK1, c-Ets-1, c-Ets-2, or c-jun. Lucif-
erase activity was determined.
transcriptional activation in a transient assay. To assess mdm2 AP-1 and Ets sites were capable of binding the
respective transcription factors, nuclear extracts werethe importance of the more downstream Ets (designated
EtsB) and AP-1 sites in the mdm2 P2 promoter in re- prepared from NIH-3T3 cells expressing DB-Raf:ER* at
various times after stimulation with 10 nM 4-HT. Thesponse to activated Raf, single point mutations were
introduced into the full-length mdm2 P2 promoter con- mdm2 AP-1 site in probe GS1 bound a complex in NIH-
3T3 nuclear extracts, the formation of which was in-struct L1 by site-directed mutagenesis. All promoter
constructs that contain mutations in one of the Ets sites creased strongly after activation of Raf (Figure 3A). This
complex was competed by 50-fold molar excess coldor the AP-1 site are nonresponsive to activated Raf any-
more (Figure 2C). Furthermore, combinations of muta- cognate competitor oligonucleotide or unlabeled GS1
probe but not by mutant AP-1 sequences or unlabeledtions of the Ets and AP-1 sites led to a significant de-
crease of basal mdm2 P2 promoter activity (Figure 2C). probe GS2 (Figure 3A). When the labeled upstream
mdm2 Ets site (EtsA) was used as probe in electropho-To exclude the occurrence of potential nonspecific mu-
tations during the generation of these constructs and retic mobility shift assays, formation of a complex could
be detected, whose intensity remained unchanged afterto address whether the Raf kinase and p53 responsive
elements are distinguishable, p53 was cotransfected Raf activation. These studies demonstrate that tran-
scription factors bind to the AP-1 and Ets elements inwith the mutated P2 promoter constructs in parallel ex-
periments. All mutated mdm2 promoter constructs the mdm2 promoter.
showed a strong induction by p53 (z10-fold) similar
to that of the parental L1 mdm2 promoter construct, Raf Regulates p53 Levels through Its Effects on Mdm2
demonstrating a clearly distinct regulation of the P2 Induction of Mdm2 protein expression is expected to
promoter by either Raf or p53 (data not shown). Overex- decrease levels of p53, since Mdm2 effectively pro-
pression of constitutively activated forms of MEK1 and motes p53 degradation (Haupt et al., 1997; Kubbutat et
MEK2, c-Ets-1, c-Ets-2, and c-jun, which are known al., 1997). To test this prediction, Raf kinase was acti-
downstream targets of Ras and Raf, led to an approxi- vated in human tumor cells expressing mutant p53, and
mately 5- to 8-fold induction of mdm2 P2 promoter activ- levels of Mdm2 and p53 proteins were analyzed by West-
ern blotting. DKO4 cells were used, in which mutantity, respectively (Figure 2D). To determine whether the
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Figure 4. The Ras/Raf/MEK/MAPK Pathway Has an Impact on
Mdm2 Expression Levels in Colon Cancer
(A) DKO4 cells expressing a EGFP-DRaf-1:ER construct were treated
with 100 nM 4-HT. Twenty-four hours later, total cellular lysates
were prepared. Equal amounts of proteins were separated by SDS-
PAGE followed by immunoblotting with antibodies against Mdm2,
p53, phosphorylated ERK1/2, or total ERK.
Figure 3. Transcription Factors Bind to the AP-1 and Ets Elements
(B) SW480 cells were cultured 48 hr in the presence or absence of
in the mdm2 Promoter
the MEK inhibitor U0126 and 10% fetal bovine serum. Equal amounts
(A) Nuclear extracts were prepared from NIH-3T3 cells expressing of proteins were electrophoretically separated prior to immunoblot-
DB-Raf:ER* at the indicated time points after stimulation with 4-HT. ting with Mdm2, phosphorylated ERK1/2, or total ERK antisera.
EMSAs were performed with 32P-labeled GS1-oligonucleotide com- (C) SW480 cells were transfected with either 1 mg of the mdm2
prising the AP-1/Ets element. In competition experiments, 50-fold promoter luciferase construct L1 or the further 59-deleted promoter
molar excess of cold AP-1 or mutated AP-1 consensus oligonucleo- construct L5, which lacks the Ras responsive elements. Transfected
tide (AP1 and mAP1, respectively) was added to the binding reaction. cells were incubated 48 hr in the presence or absence of 25 mM
(B) EMSAs were carried out with 32P-labeled GS2-oligonucleotide U0126 prior to measurement of luciferase activity. To monitor effi-
comprising the Ets site of the mdm2 promoter. cacy of the MEK inhibitor, U0126 Elk-1 activity was determined
using a commercially available Elk-1 luciferase reporter system (right
panel).
Ras had been deleted by homologous recombination
(Shirasawa et al., 1993), and a conditionally active Raf
allele (EGFP-DRaf-1:ER) was stably expressed in these 59 deleted L5 mdm2 P2 promoter construct lacking the
cells (Woods et al., 1997). Raf kinase was turned on by Ets and AP-1 binding motifs. Immediately after transfec-
addition of 4-HT, and Mdm2 levels accumulated (Figure tion, one fraction of the cells was incubated with 25 mM
4A). p53 is transcriptionally inactive in these cells (Es- U0126 for 48 hr, while the other fraction of cells was
teller et al., 2000). Hence, these data further confirm that incubated in medium without the MEK inhibitor. As dis-
Raf-dependent mdm2 transcription is independent of played in figure 4C, an approximately 7-fold decrease of
p53 transcriptional activity. Importantly, increased Raf mdm2 P2 promoter activity was observed upon U0126
activity led to a dramatic decrease of p53 protein levels treatment only in cells transfected with the Raf respon-
(Figure 4A). It is important to note that DKO4 cells, de- sive mdm2 promoter construct L1. Luciferase activity
spite harboring a mutated p53 gene, do not express of cells containing the mdm2 promoter construct L5 was
p14ARF due to hypermethylation of the p14ARF promoter significantly lower and did not change upon addition of
(Esteller et al., 2000). MEK inhibitor U0126.
SW480 cells express an activated Ras allele and a
mutant form of p53 that is transcriptionally inactive
(Sharma et al., 1993). Treatment of these cells with the Ras Mutations Lead to Attenuation
of the p53 Response and IncreasedMEK inhibitor U0126 resulted in dose-dependent de-
crease in Mdm2 protein expression (Figure 4B) consis- Survival Rate upon g-Irradiation
To investigate whether the increased Mdm2 protein lev-tent with reduced MAPK activation, showing that sus-
tained activity of the Ras/Raf/MEK/MAP kinase pathway els due to constitutive activation of Ras can prevent or
attenuate p53 induction in response to cellular stress,is necessary for high levels of Mdm2.
To examine whether decrease of Mdm2 protein ex- we g-irradiated NIH-3T3 cells or NIH-3T3 cells stably
expressing a vector encoding H-Ras (G12V). Figure 5Apression results from reduced transcriptional activity of
the mdm2 promoter upon MAPK inhibition, we mea- shows the time course of p53 induction in both cell
lines. In the parental NIH-3T3 cells, p53 protein wassured mdm2 P2 promoter activity. SW480 cells were
transfected with either the mdm2 P2 promoter construct dramatically induced after g-irradiation. Increased p53
levels are already detectable after 30 min and reach aL1, containing all the Raf-responsive elements, or the
Opposing Effects of Ras on p53
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Figure 5. Kinetics of p53 Induction upon
g-Irradiation and Radiation Survival Are Af-
fected by the Ras/Raf/MEK/MAPK Pathway
(A) Logarithmically growing cultures of NIH-
3T3 cells stably transfected with oncogenic
H-Ras(G12V) or vector alone were subjected
to g-irradiation at a dosage of 3 Gy. Proteins
were electrophoretically separated, immobi-
lized, and immunoblotted with antibodies
specific to Mdm2, p53, or b-actin. Lysates
(NIH-3T3 and NIH-3T3 Ras) were run on the
same gel. Exposure time is identical for each
protein shown, allowing direct comparison of
signal intensity.
(B) 1 3 105 NIH-3T3 cells and Ras-trans-
formed NIH-3T3 cells, respectively, were
seeded in 6-well plates. The next day, cells
were transfected with 1 mg p53-responsive
luciferase reporter and exposed to ionizing
radiation at a dosage of 3 Gy. Luciferase ac-
tivity was determined using a luminometer.
(C) Clonal survival assays were performed us-
ing the human colon cancer cell lines HCT116
and DLD-1, and their isogenic derivatives
Hke3, HCT116 p532/2, and DKO4, respec-
tively. Cells were irradiated at a dosage of 5
Gy in a 137Cs source. Survival rate for HCT116,
HCT116 p532/2, and DLD-1, respectively, was
set 100% in each set of comparisons.
(D) Time course of Mdm2 and p53 protein
levels in HCT116 cells and its derivative Hke-3
after g-irradiation (3 Gy). All lysates were run
on the same gel. Exposure time is identical
for each protein shown, allowing direct com-
parison of signal intensity.
maximum at 2 hr post irradiation. After 4 hr, p53 protein This attenuation of p53 might explain the higher resis-
tance of transformed NIH-3T3 cells toward g-irradiationlevels decreased but were still above the basal level in
nonirradiated cells. Expression of Mdm2 protein in NIH- as determined in clonal survival assays (data not shown)
(Sklar, 1988). Because Ras activation targets many3T3 cells was strongly induced beginning 1 hr after irra-
diation of the cells and peaked at 4 hr. In contrast, downstream effectors (Katz and McCormick, 1997), we
examined whether increased Mdm2 protein levels couldg-irradiation of NIH-3T3 cells harboring an activated Ras
led to only a moderate increase of p53 protein. Further- mimick Ras-mediated radioresistance. Therefore, we
established a stable NIH-3T3 cell line expressing Mdm2more, the onset of p53 induction in these cells is delayed
compared to the parental NIH-3T3 cell line (1 hr in Ras- protein under control of a mifepristone-inducible pro-
moter (NIH-3T3-imdm2). Mifepristone-treated NIH-3T3-transformed NIH-3T3 cells versus 30 min in NIH-3T3
cells). While Ras-transformed NIH-3T3 cells have al- imdm2 cells and their parental counterpart, stably
expressing the empty vector, were irradiated and subse-ready higher basal Mdm2 protein levels (originating from
the induced transcription of the mdm2 P2 promoter by quently, clonal survival assays were performed. Mdm2
expression partially rescues NIH-3T3 cells from irradia-activated Ras), there was no significant increase of
Mdm2 protein up to 4 hr after g-irradiation. Thus, NIH- tion-induced apoptosis (92% survivors in Mdm2 ex-
pressing NIH-3T3 versus 78% at 3 Gy; 49% versus 29%3T3 cells harboring an activated form of Ras are capable
of attenuating the p53 response upon g-irradiation, at 5 Gy).
To determine whether oncogenic Ras mutations con-which is consistent with their increased basal Mdm2
protein expression. fer radioresistance in human tumor cells, we performed
clonal survival assays with the human colon cancer cellNext, we wished to investigate the activity of the in-
duced p53 in response to irradiation. We examined p53 line HCT116 (wild-type p53, mutant Ras) and its deriva-
tive Hke-3, in which the mutant Ras has been deletedactivity after g-irradiation in NIH-3T3 Ras cells using
a luciferase assay. For this purpose, we transfected a by homologous recombination (Shirasawa et al., 1993).
Figure 5 shows Hke-3 express less Mdm2 protein andsynthetic p53 luciferase reporter construct into NIH-3T3
and Ras-transformed NIH-3T3 cells. Twenty-four hours more p53 than HCT116 cells, consistent with a role for
Ras in this pathway. p53 accumulated to significantlyafter transfection, cells were irradiated at a dosage of
3 Gy and luciferase activity was determined at the indi- higher levels in Hke3 cells after g-irradiation, presumably
because of lower levels of Mdm2 (Figure 5D), and radio-cated time points. Figure 5B displays the time course
of p53 activation after g-irradiation. While NIH-3T3 cells sensitivity of these cells increased dramatically (80%
survivors versus 28% survivors at 5 Gy; similar resultsreveal a 12-fold induction of p53 transcriptional activity
4 hr after irradiation, their Ras-transformed counterparts were obtained at a dosage of 1 Gy). Furthermore, inhibi-
tion of MEK in the parental HCT116 cell line throughshow only a modest p53 response (4-fold). Thus, Ras
overexpression attenuates not only p53 accumulation addition of U0126 resulted in a similar radiosensitive
phenotype as in Hke-3 cells (Figure 5D). Treatment ofbut also p53 activation in response to DNA damage.
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the p53-deficient isogenic cell line HCT116 p532/2 (Bunz
et al., 1998) with the MEK inhibitor U0126 revealed no
significant difference in radiosensitvity, showing that
Ras-mediated radioresistance is dependent on p53. The
colon cancer cell line DLD-1 harboring mutant p53 and
Ki-Ras genes shows no difference in radioresistance
compared to its counterpart DKO4, in which the mutant
Ras has been deleted (Figure 5C), suggesting that Ras
has no impact in cells lacking p53. However, it is impor-
tant to note that DLD-1 and HCT116 cells do not share
an identical genetic background. Nonetheless, this dem-
onstrates an important role for oncogenic Ras mutations
in the presence of wild-type p53 in conferring radioresis-
tance in human tumors.
Taken together, these results provide strong evidence
that activated H-Ras leads to increased basal Mdm2
protein expression, which is capable of attenuating p53
induction upon g-irradiation and renders cells more re-
sistant to the inhibitory effects of irradiation.
Attenuation of p53 Accumulation in Response
to DNA-Damaging Reagents by Activated Raf
Is Dependent on the p19ARF Status
p19ARF physically interacts with Mdm2 and consequently
stabilizes p53 (Kamijo et al., 1998; Pomerantz et al.,
1998; Stott et al., 1998). To investigate whether the pres-
ence of p19ARF can prevent Raf-induced Mdm2 from
degrading p53, we established wild-type MEFs and
p19ARF null MEFs expressing a conditionally active Raf Figure 6. Attenuation of the p53 Accumulation by Raf-induced
Mdm2 in Response to DNA Damage Depends on the p19ARF Statusallele (EGFP-DRaf-1:ER) (Kamijo et al., 1997). MEFs and
p19ARF null MEFs with induced and noninduced Raf ki- (A) Wild-type MEFs expressing a 4-Hydroxy-Tamoxifen (4-HT) in-
ducible EGFP-DRaf1:ER construct were treated with 1 mM 4-HTnase were treated with the DNA damaging reagent adria-
(right panel), or mock treated (left panel). After 24 hr, adriamycinmycin (0.25 mg/ml). As shown in Figure 6, activation of
(0.25 mg/ml) was added to the culture medium. Total protein wasRaf leads to a significant induction of Mdm2 protein
harvested at the indicated time points after addition of adriamycinafter 24 hr in both cell lines. Concomitantly, p19ARF levels
and subjected to Western blot analysis. Lysates (1/2 4-HT) wereincrease in 4-HT-treated wild-type MEFs expressing
run on the same gel. Exposure time is identical for each protein
EGFP-DRaf1:ER (Figure 6A). While Raf-induced Mdm2 shown, allowing direct comparison of signal intensity.
can attenuate p53 accumulation in response to DNA (B) p19ARF null MEFs expressing a 4-Hydroxy-Tamoxifen (4-HT) in-
damage in p19ARF null MEFs, we detect no attenuation ducible EGFP-DRaf1:ER construct were treated with 1 mM 4-HT
of p53 response in wild-type MEFs upon Raf activation (right panel), or mock treated (left panel). Twenty-four hours later,
adriamycin (0.25 mg/ml) was added to the medium.(Figures 6A and 6B). These results provide evidence that
p19ARF is capable of neutralizing the increased Mdm2
protein in response to activation of the Ras/Raf/MEK/
MAP kinase pathway. If p19ARF is not expressed due to functionally active and leads to degradation of p53. This
a targeted deletion of exon1b of the INK4A gene locus signaling pathway is intact in tumor cells expressing
(Kamijo et al., 1997), induced Mdm2 protein is fully func- activated Ras as Mdm2 protein levels decrease dramati-
tional, can bind to p53, and promote its degradation. cally after inhibiting MEK activity in these cells. Impor-
tantly, the effects of induced Mdm2 on p53 are regulated
Discussion by p19ARF. Ras therefore acts on p53 through two com-
peting pathways (Figure 7). Activation of the Ras/Raf/
MEK/MAP kinase cascade results in elevated levels ofp53 is the major known regulator of its own inhibitor,
Mdm2 (Barak et al., 1993; Wu et al., 1993). Mdm2-medi- Mdm2 protein. However, in normal cells, this pathway
also induces the expression of p19ARF (Bates et al., 1998;ated degradation of p53 occurs in the cytoplasm,
through a proteasome-dependent pathway (Haupt et al., Palmero et al., 1998), which inhibits Mdm2 activity (Tao
and Levine, 1999; Sherr and Weber, 2000). Thus, in nor-1997; Kubbutat et al., 1997). Hence, p53 and Mdm2 have
been postulated to form an autoregulatory negative mal cells, levels of p53 are determined by a balance
between opposing effects of the Ras/Raf/MEK/MAP ki-feedback loop. Regulation of mdm2 expression by p53
is thought to keep p53 function under control, thereby nase pathway. In MEFs, these opposing effects are
equivalent, and Raf is ineffective at inducing p53, de-preventing widespread p53-dependent apoptosis (Lane
and Hall, 1997; Prives, 1998). spite its effects in p19ARF. In different cell types, or even
in MEFs growing under slightly different conditions, theIn this study, we demonstrate that Mdm2 expression
is also modulated by the Ras/Raf/MEK/MAP kinase balance of these opposing pathways is likely to be differ-
ent. For example, in IMR90 human diploid fibroblasts,pathway through activation of Ets and AP-1 sites in the
P2 promoter, upstream from the p53 responsive element activated MEK leads to accumulation of p53, presum-
ably because p14ARF exceeds Mdm2 induction (Lin etand independent of its activity. Furthermore, Mdm2 in-
duced by the Ras/Raf/MEK/MAP kinase pathway is al., 1998). In Figure 7, DNA damaging agents are shown
Opposing Effects of Ras on p53
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revealed that tumors in which p53 is lost through muta-
tion or by loss of p19ARF are phenotypically similar, at
least in the early stages of tumor development (Done-
hower et al., 1992; Kamijo et al., 1997). However, tumors
that have lost p53 by direct mutation are genetically
unstable relative to those that have lost p53 function
through mutation of p19ARF (Kamijo et al., 1997). The
latter tumors may retain residual p53 function that pro-
tects cells from genetic rearrangement. Indeed, p53
transcriptional activity can be measured easily in p14ARF-
deficient tumor cells that retain low levels of p53 protein.
In these tumors, activation of Ras may suppress residual
p53 and allow tumor progression.
In addition to a role in tumor development, Ras regula-
tion of mdm2 and p53 may have important implications
in cancer treatment. Tumors carrying constitutively ac-
Figure 7. Model for the Regulation of p53 by the Ras/Raf/MEK/MAP tive forms of Ras might be more resistant to treatmentKinase Pathway
with ionizing radiation and chemotherapy. This idea is
(A) Control of p53 levels in wild-type cells. Activation of the Ras/ supported by previous observations that Ras-trans-
Raf/MEK/MAP kinase leads to transcriptional induction of p19ARF by
formed NIH-3T3 cells are relatively resistant to radiationE2F-1 via the cyclin D/CDK4/Rb pathway. Although Mdm2 protein
induced apoptosis (FitzGerald et al., 1985; Sklar, 1988).is also induced, p19ARF is capable of keeping Mdm2 functionally
Chang and coworkers examined the radiation survivalinactive. p53 accumulates rapidly after DNA damage.
of various NIH-3T3 transformants representative of the(B) Control of p53 levels in cells lacking p19ARF. Activated Ras/Raf/
various classes of oncogenes that may be involved inERK kinase induces the transcription of mdm2. Because p19ARF is
not expressed, the elevated Mdm2 protein is functionally active and the pathway. In their study, Ras, Raf, Ets, and jun overex-
attenuates p53 accumulation in response to DNA damage. pressed in NIH-3T3 cells conferred a radiation resistant
phenotype (Pirollo et al., 1993). Interestingly, chronic
Ras transformation leads to an increase in AP-1 activity
regulating p53 in a p19ARF-independent manner; how- and upregulation of c-jun (Cook et al., 1999). As overex-
ever, it is possible that p19ARF affects the magnitude pression of transcription factors c-jun and Ets mediates
or duration of the p53 response to DNA under some radioresistance, a newly transcribed protein that func-
physiological circumstances. In contrast to the Ras/Raf/ tions as an inhibitor of radiation-induced apoptosis is
MEK/MAP kinase pathway, which activates opposing likely to be involved. We provide evidence that Mdm2,
regulators of p53, E1A induces p19ARF but does not di- a well characterized inhibitor of p53 activity, mediates
the radioresistant phenotype conferred by oncogenicrectly induce Mdm2 (de Stanchina et al., 1998). E1A is
Ras. Our study demonstrates that constitutively activetherefore a potent inducer of p53.
Ras induces mdm2 transcription via activation of tran-p53 function is lost by mutation of the p53 gene in
scription factors binding to the AP-1 and Ets elementsabout 60% of all human tumors (Hollstein et al., 1991;
within the promoter. In the absence of p19ARF, elevatedLevine et al., 1991). In many of the remaining tumors,
Mdm2 protein levels resulting from constitutively activep53 function is abrogated by overexpression of Mdm2
Ras/Raf/MEK/MAP signaling lead to attenuated and di-(Oliner et al., 1992), expression of HPV E6 (Scheffner et
minished p53 response and increased survival ratesal., 1991), or by loss of p14ARF expression (Kamb et al.,
upon DNA damage. We propose that higher basal levels1994; Cordon-Cardo, 1995; Haber, 1997). In about 30%
of Mdm2 protein in Ras-transformed cells prevents theof human tumors, Ras is activated by mutation (Bos,
accumulation of stable p53 protein and the subsequent1989). Although Ras mutation and p53 mutation seem
induction of apoptosis or growth arrest in response toto be independent events (Mitsudomi et al., 1992), Ras-
DNA damage.induced Mdm2 might block p53 from inducing apoptosis
Recently, we have suggested that high levels of Mdm2or growth arrest in the early phase of tumor development
activity explain why the E1B55k-deleted adenovirusallowing coexistence of Ras mutations and wild-type
dl1520 (ONYX-015) replicates efficiently in many tumorp53. For example, Ras mutations precede p53 mutations
cell lines that retain wild-type p53 (Ries et al., 2000).in the stepwise development of colon cancer (Kinzler Oncogenic Ras, or other events that upregulate the MAP
and Vogelstein, 1996). Activation of Ras may suppress kinase pathway, could contribute to replication of dl1520
p53 during the early stages of tumor development. in these cells by elevating levels of Mdm2 protein.
Moreover, some mutant forms of p53 may retain residual In vivo studies provide further evidence for the impor-
activity (Friedlander et al., 1996). Elevated Mdm2 protein tance of Ras-controlled Mdm2 expression. Inhibition of
levels induced by Ras activation may bind those mu- oncogenic Ras activity in mouse models, through phar-
tated forms of p53 and abolish remaining p53 function. macological intervention or genetic manipulation, leads
Consistent with this, we find that the Ras/Raf/MEK/MAP to death by apoptosis (Lebowitz et al., 1997; Johnson
kinase pathway suppresses expression of mutant p53 in et al., 1997; Heimbrook and Oliff, 1998). This could be
DKO4 colon cancer cells. In addition, p53-independent due, in part, to activation of p53 through reduced ex-
transformation properties of Mdm2 have been reported. pression of Mdm2. To reevaluate the role of mdm2 and
Sarcomas harboring mdm2 gene amplifications to- p19ARF in Ras-induced tumor development in vivo, we
gether with p53 mutations show worse prognosis, when are currently investigating the contribution of this path-
compared to tumors with genetic alterations of p53 or way in a defined multistage mouse tumor model.
mdm2 alone (Cordon-Cardo et al., 1994). Therefore, In conclusion, we have shown that Mdm2 is a tran-
Ras-induced Mdm2 might contribute to tumor progres- scriptional target of the Ras/Raf/MEK/MAP kinase path-
way, and that this activation is independent of p53. Rassion in a p53-independent manner. Mouse models have
Cell
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Site-Directed Mutagenesistherefore regulates p53 through opposing pathways in-
Missense mutations were engineered into the various mdm2 pro-volving Mdm2 and its inhibitor p14ARF. In cancer cells
moter luciferase constructs by primer-mediated mutagenesis usinglacking p14ARF, Ras suppresses p53 expression. This
the QuickChange mutagenesis kit (Stratagene). All mutations weremay have important implications in cancer development
verified by sequencing.
and therapy.
Electrophoretic Mobility Shift Assay
Experimental Procedures Double-stranded oligonucleotides spanning regions 2129 bp to
291 bp (GS1), and 2171 bp to 2136 bp (GS2) of mdm2 intron
Antibodies and Reagents 1 (respective to the first nucleotide of exon 2) were labeled with
Rabbit polyclonal anti-phospho-ERK and anti-ERK antibodies were [a-32P]dCTP. Nuclear extracts of NIH-3T3 cells were prepared as
obtained from NEB, mouse monoclonal anti-b-actin antibody was described elsewhere (Andrews and Faller, 1991). EMSAs were car-
purchased from Sigma, and sheep polyclonal anti-p53 antibody ried out using 10 mg nuclear extract as previously described (Moser
Ab-7 was obtained from Calbiochem. Mouse monoclonal anti-Mdm2 et al., 1995).
antibody 2A10 was kindly provided by G. Zambetti (St. Jude Chil-
dren’s Hospital). The Dual Luciferase system and the MEK-inhibitor
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